Market size and pharmaceutical innovation

RAND Journal of Economics

Volumn 46, Issue 4, 2015, Pages 844-871

  Dubois, Pierre ^a   de Mouzon, Olivier ^b   Scott Morton, Fiona ^c   Seabright, Paul ^b  

^a Toulouse School of Economics   (France)

^b TOULOUSE SCHOOL OF ECONOMICS   (France)

^c YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84945246678     PISSN: 07416261     EISSN: 17562171     Source Type: Journal    
DOI: 10.1111/1756-2171.12113     Document Type: Article

References (35)

1. Acemoglu, D. and Linn, J. "Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry." Quarterly Journal of Economics, Vol. 119 (2004), pp. 1049-1090.
2. Adams, C.P. and Brantner, V.V. "Estimating the Cost of New Drug Development: Is It Really $802 Million?" Health Affairs, Vol. 25 (2006), pp. 420-428.
3. Adams, C.P.. "Spending on New Drug Development." Health Economics, Vol. 19 (2010), pp. 130-141.
4. Armstrong, M. and Weeds, H. "Public Service Broadcasting in the Digital World." In P. Seabright and J. von Hagen, eds., The Economic Regulation of Broadcasting Markets: Evolving Technology and Challenges for Policy. Cambridge, England: Cambridge University Press, 2007.
5. Bardey, D., Bommier, A., and Jullien, B. "Retail Price Regulation and Innovation: Reference Pricing in the Pharmaceutical Industry." Journal of Health Economics, Vol. 29 (2010), pp. 303-316.
6. Berry, S. and Waldfogel, J. "Product Quality and Market Size." Journal of Industrial Economics, Vol. 58 (2010), pp. 1-31.
7. Blume-Kohout, M.E. and Sood, N. "Market Size and Innovation: Effects of Medicare Part D on Pharmaceutical Research and Development." Journal of Public Economics, Vol. 97 (2013), pp. 327-336.
8. Blundell, R. and Powell, J.L. "Endogeneity in Nonparametric and Semiparametric Regression Models." In M. Dewatripont, L.P. Hansen, and S.J. Turnovsky, eds., Advances in Economics and Econometrics, Theory and Applications: Eighth World Congress of the Econometric Society. Vol. 2. Cambridge, England: Cambridge University Press, 2003.
9. Brekke, K.R., Grasdal, A.L., and Holmås, T.H. "Regulation and Pricing of Pharmaceuticals: Reference Pricing or Price Cap Regulation?" European Economic Review, Vol. 53 (2009), pp. 170-185.
10. Bresnahan, T.F. and Reiss, P.C. "Entry in Monopoly Markets." Review of Economic Studies, Vol. 57 (1990), pp. 531-553.
11. Bresnahan, T.F.. "Entry and Competition in Concentrated Markets." The Journal of Political Economy, Vol. 99 (1991), pp. 977-1009.
12. Cerda, R. "Endogenous Innovations in the Pharmaceutical Industry." Journal of Evolutionary Economics, Vol. 17 (2007), pp. 473-515.
13. Chen, S. "Non-Parametric Identification and Estimation of Truncated Regression Models." Review of Economic Studies, Vol. 77 (2010), pp. 127-153.
14. Civan, A. and Maloney, M. "The Effect of Price on Pharmaceutical R&D." The B.E. Journal of Economic Analysis & Policy, Vol. 9 (2009), pp. 1-24.
15. Congressional Budget Office. "Research and Development in the Pharmaceutical Industry." Congress of the United States, 2006.
16. Danzon, P. and Furukawa, M. "Prices and Availability of Biopharmaceuticals: An International Comparison." Health Affairs, Vol. 25 (2006), pp. 1353-1362.
17. Danzon, P.M. and Ketcham, J.D. "Reference Pricing of Pharmaceuticals for Medicare: Evidence from Germany, the Netherlands and New Zealand." In D.M. Cutler and A.M. Garber, eds., Frontiers in Health Policy Research. Vol. 7. Cambridge, Mass.: NBER and MIT Press, 2004.
18. Danzon, P.M., Wang, R., and Wang, L. "The Impact of Price Regulation on the Launch Delay of New Drugs-Evidence from Twenty-Major Markets in the 1990s." Health Economics, Vol. 14 (2005), pp. 269-292.
19. DiMasi, J.A., Hansen, R.W., and Grabowski, H.G. "The Price of Innovation: New Estimates of Drug Development Costs." Journal of Health Economics, Vol. 22 (2003), pp. 151-185.
20. Duggan, M. and Scott Morton, F. "The Effect of Medicare Part D on Pharmaceutical Prices and Utilization." American Economic Review, Vol. 100 (2010), pp. 590-607.
21. Finkelstein, A. "Static and Dynamic Effects of Health Policy: Evidence from the Vaccine Industry." Quarterly Journal of Economics, Vol. 119 (2004), pp. 527-564.
22. Giaccotto, C., Santerre, R.E., and Vernon, J.A. "Drug Prices and Research and Development Investment Behavior in the Pharmaceutical Industry." Journal of Law and Economics, Vol. 48 (2005), pp. 195-214.
23. Golec, J.H. and Vernon, J.A. "European Pharmaceutical Price Regulation, Firm Profitability and R&D Spending." NBER Working Paper no. 12676, 2006.
24. Grabowski, H.G. and Vernon, J.M. "Effective Patent Life in Pharmaceuticals." Int. J. Technology Management, Vol. 19 (2000), pp. 98-120.
25. Kyle, M. and McGahan, A. "Investments in Pharmaceuticals Before and After TRIPS." Review of Economics and Statistics, Vol. 94 (2012), pp. 1157-1172.
26. Lewbel, A. and Linton, O. "Nonparametric Censored and Truncated Regression." Econometrica, Vol. 70 (2002), pp. 765-779.
27. Lichtenberg, F. "Pharmaceutical Innovation and the Burden of Disease in Developing and Developed Countries." Journal of Medicine and Philosophy, Vol. 30 (2005), pp. 663-670.
28. Lichtenberg, F.R. and Duflos, G. "Pharmaceutical Innovation and the Longevity of Australians: A First Look." Advances in Health Economics and Health Services Research, Vol. 19 (2008), pp. 95-117.
29. Salop, S.C. "Monopolistic Competition with Outside Goods." The Bell Journal of Economics, Vol. 10 (1979), pp. 141-156.
30. Sood, N., de Vries, H., Gutierrez, I., Lakdawalla, D.N., and Goldman, D.P. "The Effect of Regulation on Pharmaceutical Revenues: Experience in Nineteen Countries." Health Affairs, Vol. 28 (2009), pp. w125-w137.
31. Sutton, J. Sunk Costs and Market Structure: Price Competition, Advertising, and the Evolution of Concentration. Cambridge, Mass.: MIT Press, 1991.
32. Vernon, J.A. "Examining the Link between Price Regulation and Pharmaceutical R&D Investment." Health Economics, Vol. 14 (2005), pp. 1-16.
33. Wooldridge, J.M. Econometric Analysis of Cross Section and Panel Data. Cambridge, Mass.: MIT Press, 2002.
34. Yin, W. "Market Incentives and Pharmaceutical Innovation." Journal of Health Economics, Vol. 27 (2008), pp. 1060-1077.
35. Yin, W.. "R&D Policy, Agency Costs and Innovation in Personalized Medicine." Journal of Health Economics, Vol. 28 (2009), pp. 950-962.